In a multi-centered , randomized and positive drug-controlled phase IIb clinical trial on type Y peginterferon -@ b ( NCT@ ) , forty-eight CHC patients who participated in pharmacokinetics were randomly divided into @ cohorts and treated with PegIFN ( type Y peginterferon -@ b @ g , @ g , @ g and PegIFN-@a @ g , respectively , once a week ) and ribavirin ( < @ kg , @ mg daily and@ kg , @ mg daily ) for @ weeks , and then followed up for @ weeks .